17.10.17: Not intended for U.S. and UK Media

Bayer submits its extended half-life Hemophilia A compound for marketing authorization in JapanPivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervalsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news